查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1884056

前列腺癌疫苗市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032 年）

Prostate Cancer Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 169 Pages | 商品交期: 请询问到货日

价格

前列腺癌疫苗市场成长推动因素

由于疾病盛行率上升、公众意识增强以及个人化免疫疗法的广泛应用，全球前列腺癌疫苗市场正经历快速增长。根据最近的一项研究，2024 年该市场规模为 4.904 亿美元，预计到 2025 年将达到 5.339 亿美元。预计到 2032 年将进一步成长至 11.836 亿美元，预测期内复合年增长率 (CAGR) 为 12.0%。北美地区在2024年占市场主导地位，市占率高达79.79%，这主要得益于其完善的医疗保健基础设施、免疫疗法的广泛应用以及人们对前列腺癌治疗方案的高度认知。

摄护腺癌疫苗并非预防性疫苗，而是用于治疗已确诊的疾病。这些疫苗能够活化攻击前列腺癌细胞的免疫细胞，旨在根除復发性疾病或延缓疾病进展。目前，Dendreon Pharmaceuticals LLC. 的 PROVENGE（Sipuleucel-T）是唯一获得FDA批准的疫苗，巩固了其在北美市场的领先地位。对标靶性强、毒性小的疗法的需求不断增长，以及荷尔蒙疗法和化疗等传统疗法的局限性，正在推动市场进一步扩张。

根据世界癌症研究基金会预测，2022年全球将新增1,467,854例前列腺癌病例，凸显了开发有效疗法的迫切性。免疫疗法因其副作用小、疗效持久且可与传统疗法联合应用，在治疗前列腺癌方面正得到越来越广泛的应用。

市场推动因素与机会

关键推动因素是晚期前列腺癌对荷尔蒙疗法的抗药性。雄性激素剥夺疗法 (ADT) 可降低睪固酮水平，但由于雄性激素受体突变，肿瘤会随着时间的推移产生抗药性。加州大学洛杉矶分校 Jonsson 综合癌症中心 2023 年 12 月的一项研究揭示了前列腺细胞的不同类型——基底细胞和腔细胞——这表明需要针对对激素疗法反应较差的肿瘤开发替代疗法。这推动了对疫苗的需求。

此外，个人化免疫疗法的未满足需求也带来了巨大的市场机会。各公司正投资研发新型候选疫苗，包括病毒疫苗和 DNA 疫苗。 2024年12月，Candel Therapeutics公布了其病毒免疫疗法CAN-2409联合放射疗法的III期临床试验的积极结果，证实其对中高危险局限性前列腺癌患者有效。这些进展凸显了市场的成长潜力以及持续研发投入的必要性。

市场阻碍因素与挑战

疫苗复杂且耗时的给药流程是主要阻碍因素。 Provenge需要进行白血球分离术、集中细胞处理和回输，大约需要四天时间。这种劳动密集型流程可能会因物流挑战、病患依从性问题和成本增加而限制其广泛应用。

此外，市场还面临监管挑战和较高的临床试验失败率。对细胞疗法的严格监管往往会延迟其审批和商业化进程。例如，Ventac Partners 公司的抗原疫苗 RV001 因疗效不足，于 2022 年 5 月的 II 期临床试验中失败，凸显了前列腺癌疫苗相关的财务和研发风险。

市场趋势

一个值得关注的趋势是开发旨在诱导强效抗肿瘤免疫反应的 DNA 疫苗。例如，Madison Vaccines 公司的 MVI-118 疫苗靶向转移性去势敏感性前列腺癌的雄性激素受体配体结合域。临床前和早期临床试验已证实其安全性、耐受性和延长疾病进展间隔，这反映了核酸技术在免疫疗法中日益重要的作用。与其他疗法（包括免疫检查点抑制剂，例如 ADT 和 Keytruda）合併使用的情况越来越普遍。

市场区隔分析

  • 依产品划分：PROVENGE（Sipulcel-T）将主导市场，凭藉其获得 FDA 批准以及在晚期疾病中的疗效，预计将在 2024 年占最大的市场占有率。 "其他" 细分市场预计将稳定成长，因为 PCA001 和 VTP-850 等新型临床阶段疫苗将进入研发管线。
  • 依最终用户划分：拥有专门用于白血球分离、细胞处理和疫苗接种的基础设施的医院引领市场。随着免疫疗法的普及，专科诊所和研究中心也正在成为重要的应用者。

区域展望

  • 北美：预计到 2024 年，市场规模将达到 3.913 亿美元。该地区的优势包括庞大的老年风险族群、先进的输液中心以及完善的健保报销体系。大部分疫苗将在美国普及。
  • 欧洲：第二大市场，主要得益于公众意识的提高和积极的筛检项目，例如匈牙利和义大利的 "Movember" 活动。
  • 亚太地区：预计成长最快，这主要归功于前列腺癌发生率的上升以及澳洲等国家前列腺护理中心的建立。
  • 拉丁美洲、中东和非洲：由于大众意识较低且前列腺癌疫苗价格较高，预计成长速度将放缓。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场推动因素
  • 市场阻碍因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 2024年主要国家及地区摄护腺癌盛行率
  • 主要公司产品线分析
  • 市场技术进步
  • 主要公司新产品发布
  • 主要产业趋势（併购、合作等）

第五章：全球前列腺癌疫苗市场分析、洞察与预测 (2019-2032)

  • 市场分析、洞察与预测 - 依产品分类
    • PROVENGE (Sipoleucel-T)
    • 其他
  • 市场分析、洞察与预测 - 依最终用户分类
    • 医院
    • 专科诊所
    • 其他
  • 市场分析、洞察与预测 - 依地区分类
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美前列腺癌疫苗市场分析、洞察与预测 (2019-2032)

  • 依国家分类
    • 美国各州
    • 加拿大

第七章 欧洲前列腺癌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家

第八章 亚太地区前列腺癌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 其他亚太地区国家

第九章 拉丁美洲前列腺癌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲前列腺癌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会
    • 南非
    • 其他中东和非洲国家

第十一章：竞争分析

  • 全球市占率分析（2024）
  • 公司简介
    • Dendreon Pharmaceuticals LLC.
    • Barinthus 生物治疗公司
    • 坎德尔疗法有限公司
    • 生物科技
    • 麦迪逊疫苗公司
Product Code: FBI113610

Growth Factors of prostate cancer vaccines Market

The global prostate cancer vaccines market is experiencing rapid growth due to rising disease prevalence, increasing awareness, and expanding adoption of personalized immunotherapies. According to recent insights, the market was valued at USD 490.4 million in 2024, is projected to reach USD 533.9 million in 2025, and is expected to grow to USD 1,183.6 million by 2032, reflecting a CAGR of 12.0% during the forecast period. North America dominated the market in 2024 with a 79.79% share, primarily due to well-established healthcare infrastructure, widespread access to immunotherapy, and higher awareness about prostate cancer treatment options.

Prostate cancer vaccines are therapeutic, targeting existing disease rather than prevention. The vaccines aim to activate immune cells capable of attacking prostate cancer cells, either to eradicate recurrent disease or delay disease progression. Currently, PROVENGE (Sipuleucel-T) by Dendreon Pharmaceuticals LLC. remains the only FDA-approved vaccine, reinforcing North America's leadership in the market. Rising demand for targeted, low-toxicity therapies and the limitations of traditional treatments such as hormone therapy and chemotherapy further propel market expansion.

According to the World Cancer Research Fund, 1,467,854 new prostate cancer cases were reported globally in 2022, emphasizing the urgent need for effective therapies. Immunotherapy offers durable responses with fewer side effects and can be combined with conventional treatments, enhancing its adoption in prostate cancer care.

Market Drivers and Opportunities

A key driver is the resistance to hormone therapy observed in advanced prostate cancer. Androgen deprivation therapy (ADT) reduces testosterone levels, yet tumors may develop resistance over time due to mutations in androgen receptors. Research from UCLA Jonsson Comprehensive Cancer Center in December 2023 revealed distinct basal and luminal prostate cells, highlighting that tumors less responsive to hormone therapy require alternative treatments, thereby increasing demand for vaccines.

Furthermore, the unmet need for personalized immunotherapies provides significant market opportunities. Companies are investing in novel vaccine candidates, including viral and DNA-based vaccines. In December 2024, Candel Therapeutics, Inc. reported positive Phase 3 results for CAN-2409 viral immunotherapy, combined with radiation therapy, demonstrating efficacy in intermediate-to-high-risk localized prostate cancer patients. Such developments highlight the market's growth potential and ongoing R&D investment.

Market Restraints and Challenges

The complex and lengthy administration of vaccines is a major restraint. Provenge requires leukapheresis, cell processing at a centralized facility, and reinfusion, spanning approximately four days. This labor-intensive process may limit adoption due to logistical challenges, patient compliance, and increased costs.

Additionally, the market faces regulatory challenges and high clinical trial failure rates. Strict regulations for cellular therapies often delay approvals and commercialization. For example, Ventac Partners' RV001 antigen-based vaccine failed its Phase 2 trial in May 2022 due to insufficient efficacy, illustrating the financial and developmental risks associated with prostate cancer vaccines.

Market Trends

A prominent trend is the development of DNA-based vaccines, designed to trigger potent anti-tumor immune responses. Vaccines such as MVI-118 by Madison Vaccines, Inc. target the androgen receptor ligand-binding domain for metastatic castration-sensitive prostate cancer. Preclinical and early clinical trials demonstrated safety, tolerability, and prolonged disease progression intervals, reflecting the growing role of nucleic acid technologies in immunotherapy. Integration with other therapies, including ADT and checkpoint inhibitors like Keytruda, is becoming increasingly common.

Segmentation Analysis

  • By Product: PROVENGE (Sipuleucel-T) dominates, accounting for the largest market share in 2024 due to FDA approval and efficacy in advanced cases. The "others" segment is projected to grow steadily with new clinical-stage vaccines like PCA001 and VTP-850 entering development pipelines.
  • By End User: Hospitals lead the market due to specialized infrastructure required for leukapheresis, cell processing, and vaccine administration. Specialty clinics and research centers are emerging as important adopters as immunotherapy access expands.

Regional Outlook

  • North America: Valued at USD 391.3 million in 2024, the region benefits from a geriatric population at high risk, advanced infusion centers, and comprehensive reimbursement frameworks. The U.S. accounts for the majority of adoption.
  • Europe: The second-largest market, driven by rising awareness campaigns and proactive testing programs such as the "Movember" initiatives in Hungary and Italy.
  • Asia Pacific: Poised for the fastest growth due to increasing prostate cancer prevalence and the establishment of prostate care centers in countries like Australia.
  • Latin America & Middle East & Africa: Exhibit slower growth due to high costs and limited awareness of prostate cancer vaccines.

Competitive Landscape

The market is highly consolidated, with Dendreon Pharmaceuticals LLC. leading due to PROVENGE. Other key players, including Barinthus Biotherapeutics, Candel Therapeutics, Inc., BioNTech, and Madison Vaccines, Inc., are advancing R&D pipelines and clinical trials to expand market presence and introduce novel vaccine candidates.

Conclusion

With a market size of USD 490.4 million in 2024, expected to reach USD 533.9 million in 2025, and projected to hit USD 1,183.6 million by 2032, the prostate cancer vaccines market is poised for substantial growth. Drivers include rising prevalence, resistance to hormonal therapies, and innovation in immunotherapy platforms, while regulatory complexity and administration challenges remain key hurdles. Continuous R&D, DNA-based vaccines, and expansion of treatment centers will shape market dynamics through 2032.

Segmentation By Product

  • PROVENGE (sipuleucel-T)
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Geography

  • North America (By Product, End User, and Country )
    • U.S.
    • Canada
  • Europe (By Product, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Product, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Product, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Technological Advancements in Market
  • 4.4. New Product Launches, by Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. PROVENGE (sipoleucel-T)
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By End User
    • 5.2.1. Hospitals
    • 5.2.2. Specialty Clinics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. PROVENGE (sipoleucel-T)
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By End User
    • 6.2.1. Hospitals
    • 6.2.2. Specialty Clinics
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. PROVENGE (sipoleucel-T)
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By End User
    • 7.2.1. Hospitals
    • 7.2.2. Specialty Clinics
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Rest of Europe

8. Asia Pacific Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. PROVENGE (sipoleucel-T)
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By End User
    • 8.2.1. Hospitals
    • 8.2.2. Specialty Clinics
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Rest of Asia Pacific

9. Latin America Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. PROVENGE (sipoleucel-T)
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By End User
    • 9.2.1. Hospitals
    • 9.2.2. Specialty Clinics
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. PROVENGE (sipoleucel-T)
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By End User
    • 10.2.1. Hospitals
    • 10.2.2. Specialty Clinics
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Dendreon Pharmaceuticals LLC.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. Financials (Based on Availability)
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. SWOT,Etc.
    • 11.2.2. Barinthus Biotherapeutics
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. Financials (Based on Availability)
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. SWOT,Etc
    • 11.2.3. Candel Therapeutics, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. Financials (Based on Availability)
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. SWOT,Etc
    • 11.2.4. BioNTech
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. Financials (Based on Availability)
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. SWOT,Etc
    • 11.2.5. Madison Vaccines, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. Financials (Based on Availability)
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. SWOT,Etc

List of Tables

  • Table 1: Global Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2019-2032
  • Table 2: Global Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 3: Global Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 4: North America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2019-2032
  • Table 5: North America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 6: North America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country, 2019-2032
  • Table 7: Europe Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2019-2032
  • Table 8: Europe Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 9: Europe Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 10: Asia Pacific Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2019-2032
  • Table 11: Asia Pacific Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 12: Asia Pacific Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Latin America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2019-2032
  • Table 14: Latin America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 15: Latin America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Middle East & Africa Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2019-2032
  • Table 17: Middle East & Africa Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 18: Middle East & Africa Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Prostate Cancer Vaccines Market Revenue Breakdown (USD million, %) by Region, 2024 & 2032
  • Figure 2: Global Prostate Cancer Vaccines Market Value Share (%), by Product, 2024 & 2032
  • Figure 3: Global Prostate Cancer Vaccines Market Value Share (%), by End User, 2024 & 2032
  • Figure 4: Global Prostate Cancer Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 5: North America Prostate Cancer Vaccines Market Value (USD million), by Product, 2024 & 2032
  • Figure 6: North America Prostate Cancer Vaccines Market Value Share (%), by Product, 2024
  • Figure 7: North America Prostate Cancer Vaccines Market Value (USD million), by End User, 2024 & 2032
  • Figure 8: North America Prostate Cancer Vaccines Market Value Share (%), by End User, 2024
  • Figure 9: North America Prostate Cancer Vaccines Market Value (USD million), By Country, 2024 & 2032
  • Figure 10: North America Prostate Cancer Vaccines Market Value Share (%), By Country, 2024
  • Figure 11: Europe Prostate Cancer Vaccines Market Value (USD million), by Product, 2024 & 2032
  • Figure 12: Europe Prostate Cancer Vaccines Market Value Share (%), by Product, 2024
  • Figure 13: Europe Prostate Cancer Vaccines Market Value (USD million), by End User, 2024 & 2032
  • Figure 14: Europe Prostate Cancer Vaccines Market Value Share (%), by End User, 2024
  • Figure 15: Europe Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 16: Europe Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 17: Asia Pacific Prostate Cancer Vaccines Market Value (USD million), by Product, 2024 & 2032
  • Figure 18: Asia Pacific Prostate Cancer Vaccines Market Value Share (%), by Product, 2024
  • Figure 19: Asia Pacific Prostate Cancer Vaccines Market Value (USD million), by End User, 2024 & 2032
  • Figure 20: Asia Pacific Prostate Cancer Vaccines Market Value Share (%), by End User, 2024
  • Figure 21: Asia Pacific Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 22: Asia Pacific Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 23: Latin America Prostate Cancer Vaccines Market Value (USD million), by Product, 2024 & 2032
  • Figure 24: Latin America Prostate Cancer Vaccines Market Value Share (%), by Product, 2024
  • Figure 25: Latin America Prostate Cancer Vaccines Market Value (USD million), by End User, 2024 & 2032
  • Figure 26: Latin America Prostate Cancer Vaccines Market Value Share (%), by End User, 2024
  • Figure 27: Latin America Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 28: Latin America Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 29: Middle East & Africa Prostate Cancer Vaccines Market Value (USD million), by Product, 2024 & 2032
  • Figure 30: Middle East & Africa Prostate Cancer Vaccines Market Value Share (%), by Product, 2024
  • Figure 31: Middle East & Africa Prostate Cancer Vaccines Market Value (USD million), by End User, 2024 & 2032
  • Figure 32: Middle East & Africa Prostate Cancer Vaccines Market Value Share (%), by End User, 2024
  • Figure 33: Middle East & Africa Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 34: Middle East & Africa Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 35: Global Prostate Cancer Vaccines Market Share (%), By Company, 2024